Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06077968 · ClinicalTrials.gov registry record
A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease
A clinical trial of Respiratory Syncytial Viruses, sponsored by Pfizer.
- Active
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT06077968: Active study of Respiratory Syncytial Viruses, sponsored by Pfizer.
NCT06077968 is a study of Respiratory Syncytial Viruses that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 1 participants, below the 193-participant average among 3 other Respiratory Syncytial Viruses trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06077968, a study of Respiratory Syncytial Viruses, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to learn about the effectiveness of Pfizer's ABRYSVO vaccine. This vaccine helps to prevent infections caused by Respiratory Syncytial Virus (RSV). RSV is a virus that can cause infections in the airways. These symptoms can be cold-like symptoms, but in some cases can lead to severe symptoms or hospitalization. This study uses only healthcare data that are already collected from routine visits to healthcare providers. This means that participants will not be actively enrolled in the study and there are no study treatments. The study will look at data for about two years. This study will look at patient information from: * Adults ages 60 years and older * Adults who are eligible to receive the ABRYSVO vaccination Substudy A: * This study will assess the duration of protection of ABRYSVO in adults ages 60 years and older after completion of the original study. * The substudy will look at data from subsequent RSV seasons after the first dose of ABRYSVO for about 3 years. Substudy B: * This study will assess vaccine effectiveness of ABRYSVO after revaccination in routine use, pending ACIP recommendation for revaccination. * The substudy will look at data for about 2 years after revaccination.
Primary Outcome
Adjusted for confounding factors using logistic regression. To estimate the effectiveness of ABRYSVO against RSV-related LRTD hospitalizations
Conditions Studied
Interventions
- BIOLOGICAL Prior standard of care receipt of Pfizer's ABRYSVO vaccine
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2029-05-01 |
What the registry record for NCT06077968 still lists
NCT06077968 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 193-participant average among 3 other Respiratory Syncytial Viruses trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Respiratory Syncytial Viruses appearing as the primary indexed condition, and to 1 intervention - of which Prior standard of care receipt of Pfizer's ABRYSVO vaccine is the first listed.
NCT06077968 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06077968 about?
NCT06077968 is a clinical study titled "A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease". The main purpose of this study is to learn about the effectiveness of Pfizer's ABRYSVO vaccine. This vaccine helps to prevent infections caused by Respiratory Syncytial Virus (RSV). RSV is a virus that can cause infections in the airways. These symptoms can be cold-like symptoms, but in some cases c...
What is the current status of trial NCT06077968?
This trial is currently active not recruiting. The enrollment target is 1 participants. The study started on 2023-11-01. Estimated completion is 2029-05-01.
What conditions does trial NCT06077968 study?
This clinical trial studies the following conditions: Respiratory Syncytial Viruses.
What interventions are being tested in trial NCT06077968?
The interventions under investigation include: Prior standard of care receipt of Pfizer's ABRYSVO vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06077968?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06077968 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Viruses
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
ACTIVE NOT RECRUITING
-
A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age
COMPLETED · Phase 1
-
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI